D-Enantiomeric Tau-Binding Peptides for Toxic Aggregate Breakdown
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tauopathies, including Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, subacute sclerosing panencephalitis, and corticobasal degeneration, fail to halt or slow the progression of the disease, and there is a lack of causal and life-extending therapies.
Innovation Solution
Development of peptides, specifically selected through mirror-image phage display, that bind specifically to native tau monomers, stabilizing them and shifting the equilibrium to favor natively folded conformations, thereby disassembling toxic tau aggregates into monomeric building blocks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current medications are used to treat tauopathies, then some symptoms are alleviated, but the progression of the disease cannot be slowed or stopped
Solution Approach 1:
The patent applies this principle by using D-enantiomeric peptides that mimic the structure of L-enantiomeric tau monomers. The D-peptides bind to and stabilize native tau monomers, converting the harmful aggregation process into a beneficial stabilization process. This approach directly addresses the disease progression by preventing the formation of toxic aggregates rather than merely alleviating symptoms.
Solution Approach 2:
The patent changes the enantiomeric parameter of the peptide structure from L-enantiomeric (natural) to D-enantiomeric (mirror image). This parameter change allows the peptide to bind specifically to tau monomers with high affinity while resisting proteolytic degradation, thereby providing both symptom relief and disease progression control through a fundamentally different molecular configuration.
2Stability of the object's composition
If D-peptides are designed to bind specifically to tau monomers, then the equilibrium shifts to favor natively folded conformations, but the complexity of peptide design and selection increases
Solution Approach 1:
The patent applies inversion by creating D-enantiomeric peptides as mirror images of the natural L-enantiomeric tau protein. Instead of trying to modify L-peptides to bind to tau, the invention inverts the chirality to create D-peptides that naturally bind to L-tau monomers. This inversion simplifies the design process while achieving high specificity and stability.
Solution Approach 2:
The patent uses an intermediary approach by employing phage display technology as a mediator to select and optimize D-peptide sequences. The phage display system serves as an intermediary platform that facilitates the selection of high-affinity D-peptide binders against tau monomers, reducing the complexity of direct peptide design through a systematic screening process.
3Object-generated harmful factors
If peptides are used to disassemble tau aggregates into monomers, then toxic aggregates are eliminated, but the affinity and specificity of peptide binding must be enhanced
Solution Approach 1:
The patent applies preliminary action by designing D-peptides that proactively bind to native tau monomers before they can aggregate into toxic forms. By stabilizing the monomeric state in advance, the peptides prevent the formation of oligomers and fibrils, eliminating toxic aggregates before they can cause harm rather than attempting to dismantle them after formation.
Solution Approach 2:
The patent uses copying by creating D-enantiomeric copies of the L-enantiomeric tau monomer structure. These D-peptide copies mimic the three-dimensional structure and binding interfaces of native tau, allowing them to bind with high affinity and specificity to tau monomers. This copying approach ensures precise molecular recognition while maintaining the stability needed for effective aggregate prevention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively inhibit the formation and break down toxic tau oligomers and fibrils into monomers, offering a potential therapeutic approach to treat tauopathies by specifically binding to tau monomers with enhanced affinity, reducing the progression of the diseases.
Implementation Method 1
The peptides bind specifically to native tau monomers, stabilizing them and shifting the equilibrium to favor natively folded conformations
Implementation Method 2
stabilizing them and shifting the equilibrium to favor natively folded conformations, thereby disassembling toxic tau aggregates into monomeric building blocks
Data Source
Figure 1
Figure 2a
Figure 2bA~2bB
AI summary
The invention relates to a peptide, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, or SEQ ID NO. 2, or SEQ ID NO. 3, or SEQ ID NO. 4, or SEQ ID NO. 5, or SEQ ID NO. 6, or SEQ ID NO. 7 and homologues, fragments and parts thereof, and to such a peptide for use in the treatment of tauopathies.